The identification of mutated NF-κB related genes in MM, and at the different stages of progression, highlights the concept that the activity of this signaling pathway may be heterogeneous across different molecular subtypes of this tumor, with important implications for possible tailored/targeted therapeutic approaches. Here, NFKB1 is linked to Miyoshi myopathy.